Curriculum Vitae

Stacy Loeb, MD, MSc, PhD (h.c.)www.stacyloeb.com

Twitter: @LoebStacy

EducationYear Degree Field Institution1998 Diploma (Valedictorian) Jamesville Dewitt High School2002 Bachelors (7-yr program) Medicine Northwestern University2005 MD Medicine Northwestern Feinberg School

of Medicine2013 MSc in Clinical Investigation Comparative Effectiveness New York University

Postdoctoral Training2008-2009 Courses in Epidemiology, Genetic Epidemiology & Biostatistics, Johns Hopkins

Bloomberg School of Public Health2011-2013 Masters Program in Comparative Effectiveness Research, NYU

Internships and Residencies2005-2007 Intern/Resident in Surgery/Urology, Georgetown University Hospital

Washington DC2007-2011 Resident/Chief Resident in Urology, Johns Hopkins Medical Institutions,

Baltimore, MD

Licensure and Certification2011-present NYS Medical License2013-present American Board of Urology Certification

Academic Appointments10/11-10/12 Clinical Instructor, Department of Urology, NYU School of Medicine and

Manhattan Veterans Affairs Medical Center, NY10/12-9/19 Assistant Professor, Department of Urology and Population Health, NYU School of

Medicine and Manhattan Veterans Affairs Medical Center, NY9/19-present Professor, Department of Urology and Population Health, NYU School of Medicine

and Manhattan Veterans Affairs Medical Center, NY

Other Professional Positions and Major Visiting Appointments6/11-10/11 Visiting Research Appointment, Erasmus MC, Rotterdam, Netherlands

Awards and Honors2006 National Cancer Institute Travel Scholarship to 11th Prouts Neck Meeting on Prostate

Cancer2006 UROLOGY Resident/Fellow Essay Contest, 1st Prize2008 American Urological Association Mid-Atlantic Section, Clinical Research Essay Contest-

3rd Prize

2009 American Society of Clinical Oncology (ASCO) Cancer Foundation Merit Award2010 American Urological Association/Olympus Prize Essay Contest, 2nd Prize2012 American Urological Association Prize Essay Contest, 1st Prize2013 Highest Klout Score, British Journal of Urology Social Media Awards2014 European Urology Reviewer of the Month2014 British Journal of Urology International Award for Best Social Media Campaign2014 British Journal of Urology International Award for Most Outstanding Contribution to

Social Media in Urology2015 Best Poster in Sexual Medicine and Active Surveillance Poster sessions at European

Association of Urology Congress in Madrid2015 Journal of Urology Best Reviewer in 2015 Award2016 British Journal of Urology International Award for Most Outstanding Contribution to

Social Media in Urology for #ILookLikeAUrologist Campaign2017 British Journal of Urology International Social Media Award for Best Paper2017 Dean’s List Research Incentive Award2018 Social Media Impact Award from American Urological Association for Top Tweet2019 British Journal of Urology International Award, Best Social Media Paper2019 European Urology Twitter Prize: Top Influencer at European Association of Urology

Meeting2020 Honorary Doctorate (PhD h.c.), Uppsala Universitet, Sweden

Memberships, Offices, and Committee Assignments in Professional Societies2011-present American Urological Association, Member2013-present American Urological Association Social Media Committee, Chair2013-present American Board of Urology, Diplomate2014-present European Association of Urology Guidelines Office Social Media Committee

Leadership Roles5/15-5/18 Chair, Urology Care Foundation Technology and Publications Committee3/16-present Chair, American Urological Association Social Media Work Group

Editorial PositionsEditorial Boards2016-present Journal of Clinical Oncology, Editorial Board Member2016-present Urology Times, Editorial Council2016-present Nature Reviews Urology, Advisory Board2014-present European Urology, Editorial Board Member 2014-2018 Urology Practice, Editorial Board Member 2014-present BJU International, Associate Editor- Cancer and Men’s Health 2010-2014 BJU International Editorial Board Member 2011-present Reviews in Urology Editorial Board Member

Ad Hoc Reviewing2009-present Journal reviewer (Reviews performed for >20 journals)2010 Grant Reviewer for The Prostate Cancer Charity2012 Grant Reviewer for European Research Council Synergy Grant

2012 Grant Reviewer for Prostate Cancer UK Research Awards2017-present Grant Reviewer for Prostate Cancer Foundation Awards2018 Reviewer for PCORI7/19 NIH R13 Study Section11/19 NIH R13 Study Section

Principal Clinical and Hospital Service Responsibilities2011-present Attending physician, NYU Department of Urology and Manhattan VA Hospital

Teaching Experience2009-2012 Moderator for Prostate Cancer Screening & Detection or Markers poster

sessions each year at American Urological Association Annual Meeting 5/11 American Urological Association Annual Meeting Course Faculty (Course

Title: Prostate Cancer Updates)5/12 American Urological Association Annual Meeting Course Faculty (Course

Title: Prostate Cancer Updates)6/12 NYU Minimally Invasive Prostate Cancer CME Course Faculty6/12 NYU Medical School Interclerkship Student Journal Club on Evidence-

Based Medicine12/12 NYU Updates in Adult and Pediatric Urology CME Course Faculty12/12-6/13 Research Fellowship Primary Mentor for Dr. Annelies Vellekoop (urologist-

in-training from Erasmus MC, Netherlands)- 5 peer-reviewed publications5/13 American Urological Association Annual Meeting Course Faculty (Course

Title: Prostate Cancer Updates)6/13 Advances in Prostate Imaging and Focal Ablative Treatment of Prostate

Cancer Course Faculty12/13 NYU Updates in Adult and Pediatric Urology Course Faculty1/14 Lecturer for Clinical Trials Course, NYU MSCI Program1/14 Research Fellowship Primary Mentor for Dr. Dara Lundon (urologist-in-

training from Ireland)- 2 peer-reviewed publications5/14 American Urological Association Annual Meeting Course Faculty (Course

titles: Prostate Cancer Updates, Male Health: Strategies for Managing Lifelong Wellness)

6/14 NYU Advances in Prostate Imaging and Focal Ablative Treatment of Prostate Cancer CME Course Faculty

2/15 Lecturer for Clinical Trials Course, NYU MSCI Program2/15 ASCO Genitourinary Cancer Syposium Poster Session Chair3/15 European Association of Urology Annual Meeting Faculty5/15 American Urological Association Annual Meeting Faculty (Course titles:

Prostate Cancer Updates, Male Health: Strategies for Managing Lifelong Wellness)

6/15 NYU Minimally Invasive Prostate Cancer CME Course Faculty6-7/15, 6-7/16 Primary mentor for high school student interested in medicine- 2 peer-

reviewed publications and 1 book chapter)12/15 NYU Updates in Adult and Pediatric Urology Course Faculty

6/16 NYU Advances in Prostate Imaging and Focal Ablative Treatment of Prostate Cancer CME Course Faculty

12/16 NYU Updates in Adult and Pediatric Urology Course Faculty6/17 NYU Advances in Prostate Imaging and Focal Ablative Treatment of

Prostate Cancer CME Course Faculty7/17 Primary mentor for high school student interested in medicine and NYU

medical student on research project- 1 poster presentation10/17-12/17 Primary mentor for 4 students from NYU Center for Data Science for their

capstone project12/17 NYU Updates in Adult and Pediatric Urology Course Faculty1/18-5/18 Primary mentor for 1 student from NYU Center for Data Science to do

independent study9/18 Mentorship of Postdoctoral Fellow in NYU Department of Population

Health12/18 NYU Updates in Adult and Pediatric Urology Course Faculty6/19 NYU Advances in Screening, Detection, and Treatment of Prostate Cancer7/19-9/19 Primary mentor for 2 high school students and 1 NYU medical student for

research project

Major Research Interests1. Health services/outcomes research on prostate cancer

My primary research interest is optimizing the detection and management of prostate cancer. 2. Digital technology in medicineMy other main research interest is the use of digital technology, and particularly social media, in

medicine.

Grants ReceivedPrior

Agency Title Type & # Period RoleSociety of Women in Urology

Elizabeth Pickett Award Research grant Summer 2011 PI

NYU Cancer Center

Start-Up Funds 2011-2016 PI

NYS Department of Health

Prostate Cancer Treatment: Trends and Outcomes Among US Veterans

DOH01-C30697GG-3450000

11/15-10/17 Co-I

NCI (National Institutes of Health)

Optimal Strategy for Conservative Management of Prostate Cancer

Career Development Award:K07CA178258

9/13-9/18 PI

Feldstein Medical Foundation

Educational Intervention on Active Surveillance for Prostate Cancer

Research Grant 9/18-8/19 PI

Prostate #ProstateCancer: Quantitative and Young Investigator 2016-2019 PI

Cancer Foundation

qualitative evaluation of digital media and other communications to improve prostate cancer advocacy, research and management

Award

CurrentAgency Title Type & # Period RoleNYU Perlmutter Cancer Center

Using a User-Centered Design Framework to Develop a Tailored Sleep Health Improvement Program (SHIP) for Prostate Cancer Patients and Caregivers

Developmental Grant

8/19-8/20 PI

Prostate Cancer Foundation

Technology-enhanced AcceleRation of Germline Evaluation for Therapy – The TARGET study

Challenge Award 1/20-12/22 MPI

Department of Defense

Impact of Online Prostate Cancer Information on Health Disparities

Health Disparity Research Award

3/20-3/23 PI

Invited LecturesInternational11/10 Erasmus University Medical Center (Rotterdam, The Netherlands)3/11 International Genitourinary Cancer Symposium (IGUCC 3) (Budapest, Hungary)1/12 ACME Meeting (Hemavan, Sweden)4/12 Mexican College of Urology (León, Mexico)7/12 Friends of Israel Urological Symposium (Tel Aviv, Israel)8/12 Australasian Prostate Cancer Conference (Melbourne, Australia)4/13 Mexican College of Urology (Cancun, Mexico)4/13 International Genitourinary Cancer Symposium (IGUCC 5) (Rome, Italy)8/13 Prostate Cancer World Congress (Melbourne, Australia)11/13 Mexican Society of Urology (Merida, Mexico)11/13 Dominican Society of Urology (Punta Cana, Dominican Republic)2/14 Faculty/ speaker at the IGUCC Conference (Spain)2/14 Faculty: Active Surveillance for Low Risk Prostate Cancer Conference (Amsterdam,

Netherlands)3/14 Invited lectures, Russian Ministry of Health, Institute of Urology (Moscow, Russia)4/14 Invited lecture, European Association of Urology Congress (Stockholm, Sweden)8/14 Faculty: AUA Highlights meeting in Costa Rica8/14 Invited lectures, Sociedad Colombiana de Urologia (Cartagena, Colombia)9/14 Invited lectures, Philippines Society of Uro-Oncology (Manila, Philippines)10/14 Visiting Professor, University of Toronto (Canada)10/14 Invited lecture, International Continence Society (Rio de Janiero, Brazil)10/14 Invited lecture, European Association of Urology Guidelines Office (Florence, Italy)1/15 Mexican ANUER Congress (Mexico City, Mexico)2/15 Faculty: PROSCA International Prostate Cancer Meeting (Rome, Italy)

3/15 Visiting Professor, Fundación Santa Fe de Bogotá Fundación (Bogotá, Colombia)3/15 Faculty: Second Update Course in Urology (Curso de Actualización en Urología)

(Bogotá, Colombia)3/15 Invited lectures, European Association of Urology Congress (Madrid, Spain)4/15 Invited lectures, Colegio Mexicano de Urología (Acupulco, Mexico)6/15 Invited lecture, Heinrich Warner Symposium (Hamburg, Germany)8/15 Invited lectures, Prostate Cancer World Congress (Cairns, Australia)9/15 Invited lecture, American Urological Association NY Section (Lisbon, Portugal)9/15 Lecture/Invitee: Urological Research Society (Jerusalem, Israel)10/15 Invited lecture, Congreso Venzolano de Urología (Caracas via Skype)10/15 Faculty/Invited lectures: SCU/NYU Innovations Course (Barranquilla, Colombia)11/15 Invited lecture, Atlantic Uro Oncology Meeting (Halifax, Canada)1/16 Invited lectures, Mexican ANUER Congress (Mexico City, Mexico)3/16 Faculty/Invited Lecture, European Association of Urology Congress (Munich, Germany)4/16 Invited lectures: Colegio Mexicano de Urología (Puebla, Mexico)4/16 Invited Lecture/Panel, John Fitzpatrick Irish Prostate Cancer Conference (Dublin, Ireland)7/16 Faculty, Friends of Israel Urology Symposium (Tel Aviv, Israel)7/16 Invited lectures: Asociación Mexicana de Urología Oncológica (Acapulco, Mexico)8/16 Australasian Prostate Cancer Conference (Melbourne, Australia)8/16 Invited lectures: Macquarie University (Sydney, Australia)9/16 Faculty/Invited lectures: UROBI meeting (Cancun, Mexico)10/16 Faculty/Invited lectures: Congreso de la Confederación Americana de Urología (Panama)10/16 Invited lectures: Korean Urological Association Meeting (Seoul, Korea)10/16 Invited lectures, Royal Society of Medicine (London, UK)11/16 Faculty/Course Director: World Congress of Endourology (Cape Town, South Africa)1/17 Invited Lectures, Royal Society of Medicine (Lake Tahoe, NV)1/17 Invited Lectures, Issues & Controversies in Urologic Cancer (Mont Tremblant, Quebec)2/17 Sociedad Mexicana de Urologia/AUA Highlights Meeting (Acapulco, Mexico)3/17 Faculty/Course/Moderator: European Association of Urology Congress (London, UK)4/17 Lectures on prostate cancer markers in Australia (Brisbane, Adelaide, Sydney, Melbourne,

Hobart)6/17 Invited lecture, Heinrich Warner Symposium (Hamburg, Germany)6/17 Invited speaker, Canadian Urological Association Meeting (Toronto, Canada)6/17 Faculty/ lectures, PROSCA International Prostate Cancer Meeting (Lisbon, Portugal)10/17 Keynote speaker, New Zealand Urologic (Tauranga, New Zealand)12/17 Invited presentation, Association of Academic European Urologists (Dresden, Germany)4/18 Invited lecture, Surgery in the 3rd Millennium: the Future is Female (Milan, Italy)8/18 Invited lectures, Prostate Cancer World Congress (Brisbane, Australia)9/18 Invited lecture, iTRUST International Translational Research Uro-Sciences Team (Rome,

Italy)10/18 Visiting professor and Morales Lecture, Queens University (Kingston, Ontario)11/18 State-of-the-Art Lecture, Association of Academic European Urologists (Rome, Italy)1/19 Invited lecture, Hot Topics in Uro-Oncology (Zurich, Switzerland)4/19 Invited lecture and live surgery moderator, Surgery in the 3rd Millennium: the Future is

Female (Milan, Italy)

7/19 Invited lecture and live surgery moderator, Challenges in Laparoscopy & Robotics (Barcelona, Spain)

11/19 Invited lectures/Moderator, Clinical Oncology Society of Australia (Adelaide, Australia)1/20 Invited lecture, Uppsala University Honorary Doctorate (Uppsala, Sweden)

National/Local6/12 American College of Physicians New York Chapter (Debate on PSA)9/12 Gensler Corporation (Wellness Lecture on Prostate Cancer Risks and Prevention)9/12 Bellevue Hospital Med-Surg Conference (Non-Operative Management of Prostate Cancer)9/12 NYU Radiation Oncology Grand Rounds (PSA, Prostate Biopsy and Active Surveillance)9/12 Yale/NYU Using Modeling to Inform Public Health (UMPH) Conference (Active

Surveillance)9/13 NYU Radiation Oncology Grand Rounds (PSA, Active Surveillance)11/13 Mount Sinai Department of Urology Grand Rounds (Prostate Cancer Markers)12/13 National Cancer Institute Prostate SPORE-Society of Urologic Oncology Workshop2/15 Montefiore Department of Urology Grand Rounds (Prostate Cancer Screening & Active

Surveillance)8/15 Invited lecture, Future Directions in Urology Symposium (Colorado Springs, Colorado)9/15 Florida Urologic Society 2015 Meeting (Orlando, Florida)9/15 Cancer Research & Oncology Virtual Conference (Online symposium)11/15 Visiting Professor, Albany Medical College (Albany, NY)12/15 Visiting Professor, Hackensack Hospital (Hackensack, NJ)12/15 NYU Urology Grand Rounds (Biostatistics)1/16 Invited lecture, University of Southern California Institute of Urology Grand Rounds (via

Skype)1/16 Invited lectures, 26th International Prostate Cancer Update (Vail, CO)1/16 Invited lecture, Society of Women in Urology 2016 Annual Meeting (Scottsdale, AZ)2/16 Invited lectures, University of Southern California Institute of Urology 1st Practical

Urology Conference (Los Angeles, CA)3/16 SUNY Downstate Department of Urology Grand Rounds (Brooklyn, NY)5/16 Plenary lecture, 2016 American Urological Association meeting (San Diego, CA)6/16 Plenary lecture, 2016 American Society of Clinical Oncology meeting (Chicago, IL)6/16 Visiting Professor, University of Rochester (Rochester, NY)8/16 Faculty, Advanced Robotic Urology and Prostate Cancer Update (Napa, California)9/16 Podium Presentation, Urological Research Society (NY, NY)10/16 Invited lecture, Prostate Cancer Foundation Scientific Retreat (Carlsbad, California)1/17 Faculty, USC Practical Urology Course (Los Angeles, California)5/17 Plenary, SUO lecture and course faculty, 2017 AUA meeting (Boston, MA)5/17 Grand Rounds, University of Pennsylvania Urology & Pathology Departments

(Philadelphia, PA)6/17 Grand Rounds, Washington University (St Louis, MO)10/17 Panelist, Prostate Cancer Foundation Retreat (Washington, DC)11/17 Chairman's Rounds, Johns Hopkins Hospital (Baltimore, MD)1/18 Invited lectures, Society of Women in Urology Winter Meeting (Las Vegas, NV)2/18 Invited lectures, University of Southern California 3rd Practical Urology Conference (Los

Angeles, CA)

5/18 Invited lecture/panelist, LA Live Advanced Robotic & Open Surgery Symposium (Los Angeles, CA)

5/18 Italian Society of Urology (SIU)-AUA Meeting (San Francisco, CA)5/18 Confederacion Americana de Urología (CAU)- AUA Meeting (San Francisco, CA)12/18 Visiting Professor, Henry Ford Hospital (Detroit, MI)1/19 Grand Rounds, University of California San Francisco (San Francisco, CA)5/19 Plenary Lecture, American Urological Association 2019 Meeting (Chicago, IL)9/19 Invited Lectures, Northeastern Section American Urological Association Meeting

(Syracuse, NY)10/19 Research Seminar, Division of General Internal Medicine, NYU (NY, NY)10/19 American Association of Clinical Urologists 2019 Annual Meeting (Washington DC)10/19 Visiting Professor, Hackensack University Medical Center (Hackensack, NJ)10/19 Research Seminar, INSPIRE Seminar Series, Manhattan Veterans Affairs (NY, NY)10/19 Moderator/Speaker, Prostate Cancer Foundation-UsTOO Patient Forum (Carlsbad, CA)11/19 Invited Speaker, Leapsmag Culture Leap (Malibu, CA)12/19 Invited Lecture, Memorial Sloane Kettering Cancer Center

Workshops/Courses2009 Journal of Urology Peer Review Seminar2013 Hands-On Prostate Ultrasound Course at American Urological Association meeting6/15 Qualitative Research Course at Columbia University8/15 Prostate MRI & Biopsy Masterclass at Prostate Cancer World Congress6/17 Mentored Training for Dissemination and Implementation Research in Cancer (MT-DIRC)4/18 Harvard Catalyst Online Course: Introduction to Mixed Methods Research6/18 Mentored Training for Dissemination and Implementation Research in Cancer (MT-DIRC)

OtherMedia Work2011-present Radio Host for Men's Health Show on Doctor Radio (Sirius XM Satellite Radio)- 2

hour live segment from 6-8pm EST on men’s health issues, 1-2x/month2013-present Press conference moderator, American Urological Association annual meetings2014 Invited social media director for St. Gallen Prostate Cancer Consensus Conference

(Switzerland)

Community Service2001 Spanish translator in London2001-2002 Monthly volunteer work at Spanish-speaking medical clinic2002 Medical mission trips to Nicaragua and Mexico City5/17-8/17 Founder/Administrator for Poodle Rescues & Rehomes Facebook Community2017-present Volunteer at Best Friends Animal Society (4-6h/month)

Outreach9/12 NYU Cancer Institute Community Education Series (Lecture on PSA Screening)10/12 NYU Cancer Institute Prostate Cancer Support Group Lecture (Treatment Options)5/14 NYU Cancer Institute Community Education Series (Active Surveillance)6/15 NYU Cancer Institute Community Education Series (Prostate Cancer Markers)

9/15 AUA Prostate Cancer Tweetchat Moderator9/15 NYU Cancer Institute Community Education (Active Surveillance & Markers)9/16 NYU Cancer Institute Community Education (Prostate Cancer Diagnosis &

Treatment)9/17 NYU Cancer Institute Community Education (Prostate Cancer Awareness,

Screening Guidelines, Active Surveillance)9/18 UsTOO International Prostate Cancer Pathways for Patients &

Caregivers Event in Englewood, NJ (Prostate Cancer Detection & Treatment)3/19 NYU Perlmutter Cancer Center Community Education (Social Media in Cancer)

Basic Science Research Experience7/96-8/96 Summer research at Russian Academy of Sciences (Russia)5/06-12/06 “Optimization of Comet Assay for Quantification of DNA Repair Capacity in

Human Whole Blood.” (Georgetown University, 5/06- 12/06)11/03-11/04 “Differential Expression of Farnesyl Diphosphate Synthase (FPPS) in Prostate

Cancer Tissue.” (Northwestern University)

Bibliography

Original Reports/Peer-Reviewed1. Loeb S, Han M, Roehl KA, Antenor JV, and Catalona WJ. “Accuracy of Prostate Weight

Estimation by Digital Rectal Exam (DRE) Versus Transrectal Ultrasonography (TRUS).” Journal of Urology, January 2005; 173: 63-5.

2. Loeb S, Vardi IY, and Nadler RB. “Contemporary Management of Urosepsis: Updated Critical Care Guidelines.” Contemporary Urology, July 2005

3. Catalona WJ and Loeb S. “The PSA Era is Not Over for Prostate Cancer” European Urology, October 2005; 48: 541-5.

4. Nadler RB, Loeb S, Roehl KA, Antenor JV, Eggener SE, and Catalona WJ. “Use of 2.6 ng/ml Prostate Specific Antigen (PSA) Prompt for Biopsy for Men Over Age 60” Journal of Urology, December 2005; 174: 2154.

5. Loeb S, Roehl KA, Antenor JV, Catalona WJ, Suarez BK, and Nadler RB. “Baseline Prostate Specific Antigen (PSA) Compared with Median PSA for Age Group as Predictor of Prostate Cancer Risk in Men Under 60 Years of Age” Urology, February 2006; 67: 316.

6. Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JV, Yap RL, and Catalona WJ. “Pathologic Characteristics of Prostate Cancer Detected Through Prostate-Specific Antigen (PSA)- Based Screening” Journal of Urology, March 2006; 175: 902.

7. Catalona WJ, Loeb S, and Han M. “Viewpoint: Expanding Prostate Cancer Screening.” Annals of Internal Medicine, March 2006; 144: 441.

8. Nadler RB, Loeb S, Clemens JQ, Batler RA, Gonzalez CM, and Vardi IY. “A Prospective Study on Laparoscopic Radical Nephrectomy: Is Transperitoneal, Retroperitoneal, or Hand-Assisted the Best Approach?” Journal of Urology, April 2006; 175: 1230.

9. Loeb S and Nadler RB. “Management of the Complications of External Beam Radiotherapy and Brachytherapy.” Current Urology Reports, May 2006; 7: 200.

10. Catalona WJ and Loeb S. “More Effective Use of PSA” Urologic Oncology: Seminars and Original Investigations, May-June 2006; 24: 177.

11. Loeb S, Yu X, Roehl KA, Antenor JV, Han M, and Catalona WJ. “Lymphovascular Invasion in Radical Prostatectomy Specimens: Prediction of Adverse Pathology and Biochemical Progression” Urology, July 2006; 68: 99.

12. Nadler RB, Loeb S, and Vardi IY. “The Use of BioGlue in Laparoscopic Partial Nephrectomy.” Urology, August 2006; 68: 416.

13. Loeb S and Catalona WJ. “What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?” Nature Clinical Practice Urology, August 2006; 3: 418.

14. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JAV, and Catalona WJ. “Survival Results in Screen-Detected Prostate Cancer Patients Versus Physician-Referred Patients Treated With Radical Prostatectomy: Early Results.” Urologic Oncology: Seminars and Original Investigations, November-December 2006; 24: 465.

15. Roehl KA, Loeb S, Antenor JA, Corbin N, and Catalona WJ. “Characteristics of Patients with Familial Prostate Cancer Versus Sporadic Cases.” Journal of Urology, December 2006; 176: 2438.

16. Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, and Catalona WJ. “Comparison of Different Methods for Calculating PSA Velocity: Importance of Time Interval Prior to Diagnosis of Prostate Cancer.” Journal of Urology, December 2006; 176: 2427.

17. Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, and Catalona WJ. “Does Body Mass Index Affect Outcomes Following Radical Prostatectomy?” Journal of Urology, January 2007; 177: 102.

18. Loeb S, Roehl KA, Yu X, Han M, and Catalona WJ. “Use of PSAV to Follow Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia (HG-PIN) on Prostate Biopsy.” Urology, January 2007; 69: 108.

19. Loeb S and Catalona WJ. “Cancer Biomarkers: Discovery and Validation.” Cancer Letters, January 2007

20. Catalona WJ and Loeb S. “PSA Is an Effective Marker for Prostate Cancer.” AUANews, January 2007 (Part 1) and February 2007 (Part 2)

21. Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, and Sheinfeld J. “Pathologic Findings and Clinical Outcomes of Patients Undergoing Retroperitoneal Lymph Node Dissection Following Multiple Chemotherapy Regimens for Metastatic Testicular Germ Cell Tumors.” Cancer, February 2007; 109: 528.

22. Loeb S, Roehl KA, Catalona WJ, and Nadler RB. “PSA Velocity Threshold for Predicting Prostate Cancer in Young Men.” Journal of Urology, March 2007; 177: 899.

23. Loeb S and Catalona WJ. “Advances in Prostate Cancer Testing.” Clinical Laboratory News, March 2007; 33: 12.

24. Loeb S and Catalona WJ. “PSA as a Screening Test for Prostate Cancer.” ACP Observer, April 2007

25. Yu X, Loeb S, Han M, Suarez BK, Roehl KA, and Catalona WJ. “The Association Between Total PSA and PSA Velocity.” Journal of Urology, April 2007; 177: 1298.

26. Loeb S and Catalona WJ. “Prostate cancer screening: Where are we now?” Contemporary Urology, May 2007

27. Lynch J and Loeb S. “The Role of HIFU in Prostate Cancer.” Current Oncology Reports, May 2007; 9: 22.

28. Sotelo R, Mora K. E, Perez L. H, Novoa J, Castillo M, Carmona O, De Andrade R, Loeb S, and Catalona WJ. “Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting From Different Assays for Free and Total Prostate-Specific Antigen (PSA).” Urology, June 2007; 69: 1143.

29. Loeb S, Smith N, Roehl KA, and Catalona WJ. “Intermediate-Term Potency, Continence and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Advanced Prostate Cancer.” Urology, June 2007; 69: 1170.

30. Graif T, Yu Y, Loeb S, Gashti SN, Griffin S, Han M, Roehl KA, Suarez BK, and Catalona WJ. “Underdiagnosis and Overdiagnosis of Prostate Cancer.” Journal of Urology, July 2007; 178: 88.

31. Loeb S and Catalona WJ. “Early versus delayed intervention for prostate cancer: the case for early intervention.” Nature Clinical Practice Urology, July 2007; 4: 348.

32. Loeb S and Catalona WJ. “Counterpoint: the case for active treatment.” Journal of the National Comprehensive Cancer Network, August 2007; 5: 699.

33. Griffin C, Yu X, Loeb S, Desireddi VN, Han M, and Catalona WJ. “Pathologic Features after Radical Prostatectomy for Potential Candidates for Active Monitoring.” Journal of Urology, September 2007; 178: 860.

34. Rubenstein RA, Zhao LC, Loeb S, Shore DM, and Nadler RB. “Prestenting Improves Ureteroscopic Stone-Free Rates.” J Endourol, November 2007; 21: 1277.

35. Desireddi VN, Roehl KA, Loeb S, Yu X, Griffin C, Kundu S, Han M, and Catalona WJ. “Progression-Free Survival Rates for Radical Prostatectomy in the PSA Era.” Urology, November 2007; 70: 950.

36. Loeb S and Catalona WJ. “Open Radical Retropubic Prostatectomy.” Urologic Oncology: Seminars and Original Investigations, November-December 2007; 25: 494.

37. Loeb S, Yu X, Roehl KA, Nadler RB and Catalona WJ. “PSA Velocity Thresholds in Men with Total PSA <4 ng/ml.” Journal of Urology, December 2007; 178; 2348.

38. Okotie O, Roehl KA, Han M, Loeb S, Gashti SN, and Catalona WJ. “Characteristics of Prostate Cancer Detected by Digital Rectal Examination Only.” Urology December 2007; 70: 1117.

39. Loeb S and Catalona WJ. “What to do with an abnormal PSA test.” The Oncologist, March 2008; 13: 299.

40. Loeb S, Roehl KA, Catalona WJ, and Nadler RB. “Is the Utility of PSA Velocity for Prostate Cancer Detection Affected by Age?” BJU International, April 2008; 101: 817.

41. Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, and Catalona WJ. “Comparison of PSA Velocity of Screened Versus Referred Patients with Prostate Cancer.” Journal of Urology, April 2008; 179: 1340.

42. Zhao LC, Han JS, Loeb S, Tenggardjaja C, Rubenstein R, Smith ND, and Nadler RB. “Thoracic Complications of Urological Laparoscopy: Correlation Between Radiographic Findings and Clinical Manifestations.” J Endourol, April 2008; 22: 607.

43. Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, and Catalona WJ. “Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles.” Journal of Urology, June 2008; 179: 2197.

44. Loeb S, Hernandez DH, Mangold LA, Humphreys EB, Agro M, Walsh PC, Partin AW, and Han M. “Progression after Radical Prostatectomy for Men in their Thirties Compared to Older Men.” BJU International, June 2008; 101: 1503.

45. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, and Catalona WJ. “The Relationship of PSA Velocity to Histologic Findings in a Prostate Cancer Screening Program.” Urology, June 2008; 71: 1016.

46. Catalona WJ and Loeb S. “Commentary on the Recommendations of The American College of Preventive Medicine on Prostate Cancer Screening.” Medscape Urology (online)

47. Loeb S, Roehl KA, Viprikasit DP, and Catalona WJ. “Long-Term Rates of Undetectable PSA with Initial Observation and Delayed Salvage Radiotherapy after Radical Prostatectomy.” European Urology, July 2008; 54: 88.

48. Loeb S, Roehl KA, Thaxton CS, and Catalona WJ. “Combined Prostate-Specific Antigen Density and Biopsy Features to Predict ‘Clinically Insignificant’ Prostate Cancer.” Urology, July 2008; 72: 143.

49. Loeb S, Sutherland DE, D’Amico AV, Roehl KA, and Catalona WJ. “PSA Velocity is Associated with Gleason Score in Radical Prostatectomy Specimen: Marker for Prostate Cancer Aggressiveness.” Urology, June 2008 (epub).

50. Macejko AM, Pazona JF, Loeb S, Kimm S, and Nadler RB. “Management of Distal Ureter in Laparoscopic Nephroureterectomy- A Comprehensive Review of Techniques.” Urology, July 2008 (epub).

51. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB. “PSA Doubling Time Versus PSA Velocity to Predict High-Risk Prostate Cancer: Data from the Baltimore Longitudinal Study of Aging.” European Urology, July 2008 (epub).

52. Loeb S. “Does PCA3 Help Identify Clinically Significant Prostate Cancer?” European Urology, July 2008 (epub).

53. Martin NE, Chen MH, Catalona WJ, Loeb S, Roehl KA, and D’Amico AV. “The Influence of Serial Prostate-Specific Antigen Screening on the PSA Velocity at Diagnosis.” Cancer, August 2008; 113: 717.

54. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, and Walsh PC. “Does Prostate Growth Confound PSA Velocity: Data from the Baltimore Longitudinal Study of Aging.” Journal of Urology, October 2008; 180: 1314.

55. Nguyen PL, Chen MH, Catalona WJ, Alexander BM, Roehl KA, Loeb S, and D’Amico AV. “Biochemical Recurrence Following Radical Prostatectomy for Prevalent vs. Incident Cases of Prostate Cancer: Implications for Management.” Cancer, October 2008 (epub)

56. Loeb S and Schaeffer EM. “Does Primary Androgen-Deprivation Therapy Improve Survival for Localized Prostate Cancer?” Aging Health, October 2008; 4: 451.

57. Loeb S, Roehl KA, Helfand BT, and Catalona WJ. “Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.” Urology, October 2008; 72: 887.

58. Makarov DV, Loeb S, Getzenberg RH, and Partin AW. “Biomarkers for Prostate Cancer.” Annual Reviews in Medicine, October 2008 (epub).

59. Loeb S and Partin AW. “Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility.” Reviews in Urology, Fall 2008; 10: 304.

60. Loeb S, Chan DW, Sokoll L, Kan D, Mikolajczyk SD, Maggiore J, Mondo DM, Griffin CR, and Catalona WJ. “PSA Standardization Bias Could Affect Clinical Decision-making.” Journal of Urology, November 2008 (epub).

61. Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, and Carter HB. “The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.” European Urology, November 2008 54: 978.

62. Loeb S, Lotan T, Thornton K, and Schoenberg MP. “A Case of Gastrointestinal Stromal Tumor Diagnosed on Prostate Biopsy.” Nature Clinical Practice Urology, December 2008 (epub).

63. Loeb S and Catalona WJ. “Diagnosis and Treatment of Prostate Cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.” Medical Economics, December 2008; 85: 36.

64. Loeb S, Gashti SN, and Catalona WJ. “Exclusion of Inflammation in the Differential Diagnosis of an Elevated Prostate-Specific Antigen (PSA).” Urologic Oncology: Seminars and Original Investigations, Jan-Feb 2009; 27: 64.

65. Loeb S and Catalona WJ. “What is the Role of Digital Rectal Examination in Men Undergoing Serial Screening of Serum PSA?” Nature Clinical Practice Urology, February 2009; 6: 68.

66. Helfand BT, Mongiu AK, Kan D, Kim DY, Loeb S, Roehl KA, Meeks JJ, Smith ND, and Catalona WJ. “Outcomes of Radical Prostatectomy for Patients with Clinical Stage T1a and T1b Disease.” BJU International, February 2009 (epub).

67. Loeb S and Carter HB. “Words of Wisdom: Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.” European Urology, February 2009; 55: 523.

68. Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, and Metter EJ. “Prostate Specific Antigen Testing Among the Elderly: When to Stop?” Journal of Urology, April 2009; 181: 1606.

69. Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, and Sokoll LJ. “Investigation of Human Anti-Mouse Antibodies As Potential Cause of Postprostatectomy PSA Elevation.” Urology, May 2009; 73: 947.

70. Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, and Shapiro E. “Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.” Reviews in Urology, Spring 2009; 11: 82.

71. Loeb S and Partin AW. “Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention.” Reviews in Urology, Spring 2009; 11: 114.

72. Meeks JJ, Loeb S, Helfand BT, Kan D, Smith ND, and Catalona WJ. “Characteristics of Prostate Cancers Detected at Prostate-Specific Antigen Levels Less than 2.5 ng/ml.” Journal of Urology, June 2009; 181: 2515.

73. Helfand BT, Loeb S, Meeks JJ, Fought AJ, Kan D, and Catalona WJ. “Pathologic Outcomes Associated with the 17q Prostate Cancer Risk Variants.” Journal of Urology, June 2009; 181: 2502.

74. Loeb S. “Prostate Cancer: Is PSA Velocity Useful?” Nature Reviews Urology, June 2009; 6: 305.

75. Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, Ferrucci L, and Metter EJ. “Single Nucleotide Polymorphisms and the Likelihood of Prostate Cancer at a Given Prostate-Specific Antigen Level.” Journal of Urology, July 2009; 182: 101.

76. Trock BJ, Guo CC, Gonzalgo ML, Magheli A, Loeb S, and Epstein JI. “Impact of Tertiary Gleason Patterns on Biochemical Recurrence Following Radical Prostatectomy: Proposal for a Modified Gleason Scoring.” Journal of Urology, August 2009 epub.

77. Loeb S, Kettermann A, Carter HB, Metter EJ, Ferrucci L, and Walsh PC. “Prostate Volume Changes Over Time: Results From the Baltimore Longitudinal Study of Aging.” Journal of Urology, August 2009 epub.

78. Loeb S, Epstein JI, Humphreys EB, and Walsh PC. “Does Perineural Invasion on Prostate Biopsy Predict Adverse Prostatectomy Outcomes?” BJU International, August 2009 epub.

79. Loeb S and Partin AW. “Randomized Trials of Prostate Cancer Screening.” Reviews in Urology, Summer 2009; 11: 179.

80. Loeb S and Schaeffer EM. “Risk Factors, Prevention, and Early Detection of Prostate Cancer.” Primary Care Clinics of North America, September 2009; 36: 603.

81. Loeb S and Schaeffer EM. “Optimal Therapy in Localized Prostate Cancer: An Unfolding Story.’” Oncology (Williston Park), September 2009; 23: 843.

82. Loeb S, Kan D, Helfand BT, Gashti SN, Nadler RB, and Catalona WJ. “Is Statin Use Associated with Prostate Cancer Aggressiveness?” BJU International 2009, Nov 3 epub.

83. Loeb S, Schaeffer EM, Trock BJ, Humphreys EB, Epstein JI, and Walsh PC. “What are the Outcomes of Radical Prostatectomy for High-Risk Prostate Cancer?” Urology 2009, Nov 19 epub.

84. Loeb S, Helfand BT, Kan D, Isaacs WB, and Catalona WJ. “Does Diabetes Mellitus Modify the Association between 17q12 Risk Variant and Prostate Cancer Aggressiveness?” BJU International, November 2009; 104: 1200.

85. Loeb S and Carter HB. “Limitations and Use of PSA Derivatives in the Screening and Risk Stratification of Prostate Cancer.” Urologic Oncology: Seminars and Original Investigations, Nov-Dec 2009; 27: 583.

86. Loeb S. “Editorial Comment on ‘Impact of Positive Apical Surgical Margins on Likelihood of Biochemical Recurrence After Radical Prostatectomy.’” Journal of Urology, December 2009; 182: 2701.

87. Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, and Metter EM. “Should Prostate-specific Antigen be Adjusted for Body Mass Index? Data From the Baltimore Longitudinal Study of Aging.” Journal of Urology, December 2009; 182: 2646.

88. Loeb S, Partin AW, and Schaeffer EM. “Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?” Reviews in Urology, Winter 2010; 12: 20.

89. Loeb S and Partin AW. “What is the true mortality benefit of prostate-specific antigen screening?” Reviews in Urology, Winter 2010; 12: 66.

90. Loeb S and Partin AW. “Open versus minimally invasive radical prostatectomy.” Reviews in Urology, Winter 2010; 12: 20.

91. Loeb S, Schaeffer EM, and Epstein JI. “The Vanishing Prostate Cancer Phenomenon.” Urology, January 2010 epub.

92. Loeb S, Roehl KA, Helfand BT, Kan D, and Catalona WJ. “Can PSA Velocity Thresholds Reduce the Detection of Insignificant Prostate Cancer?” Journal of Urology, January 2010; 183: 112.

93. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, and Sokoll LJ. “Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program.” Journal of Urology, February 2010; 183: 534.

94. Thaxton CS, Loeb S, Roehl KA, Kan D, and Catalona WJ. “Treatment Outcomes of Radical Prostatectomy in Potential Candidates for 3 Published Active Surveillance Programs.” Urology, February 2010; 75: 414.

95. Schaeffer EM, Loeb S, and Walsh PC. “The Case for Open Radical Prostatectomy.” Urological Clinics of North America, February 2010; 37: 49.

96. Catalona WJ and Loeb S. “Prostate Cancer Screening and Determining the Appropriate Prostate-Specific Antigen Cutoff Values.” Journal of the National Comprehensive Cancer Network, February 2010; 8: 265.

97. Loeb S. “Prostate Biopsy: A Risk-Benefit Analysis.” Journal of Urology, March 2010; 183: 852.

98. Makarov DV, Loeb S, Landman AB, Nielsen ME, Gross CP, Leslie DL, Penson DF, and Desai RA. “Regional Variation in Total Cost per Radical Prostatectomy in the Heathcare Cost and Utilization Project Nationwide Inpatient Sample Database.” Journal of Urology, April 2010; 183: 1504.

99. Loeb S and Catalona WJ. “Prostate Cancer: Utility of the Riskindicator Model in Screening.” Nature Reviews Urology, April 2010; 7: 184.

100. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, and Catalona WJ. “[-2] Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study.” Journal of Urology, April 2010; 183: 1355.

101. Loeb S, Epstein JI, Ross AE, Schultz L, Humphreys EB, and Jarow JP. “Benign Prostate Glands at the Bladder Neck Margin in Robotic vs. Open Radical Prostatectomy.” BJU International, May 2010; 104: 1446. (Initiation of BJU International Blog Section)

102. Carvalhal GF, Griffin CR, Kan D, Loeb S, and Catalona WJ. “Reducing Blood Loss in Open Radical Retropubic Prostatectomy with Prophylactic Periprostatic Sutures.” BJU International, May 2010; 105: 1222.

103. Loeb S, Kan D, Yu X, Roehl KA, and Catalona WJ. “Preoperative Prostate Specific Antigen Doubling Time is Not a Useful Predictor of Biochemical Progression After Radical Prostatectomy.” Journal of Urology, May 2010; 183: 1816.

104. Kettermann AE, Ferrucci L, Trock BJ, Metter EJ, Loeb S and Carter HB. “Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer.” BJU International, May 2010 epub.

105. Loeb S and Catalona WJ. “Prostate-specific antigen screening: pro.” Current Opinion in Urology, May 2010; 20: 185.

106. Helfand BT, Loeb S, Kan D, Catalona WJ. “Number of prostate cancer risk alleles may identify possibly ‘insignificant’ disease.” BJU International, June 2010 epub.

107. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, and Walsh PC. “Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.” Journal of Clinical Oncology, June 2010; 28: 2810.

108. Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, and Walsh PC. “Prostate-specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.” Journal of Urology, July 2010; 184: 157.

109. Loeb S, Carter HB, Schaeffer EM, Ling SM, Kettermann A, Ferrucci L, and Metter EJ. “Bone Mineral Content and Prostate Cancer Risk: Data from the Baltimore Longitudinal Study of Aging.” BJU International, July 2010; 106: 28.

110. Helfand BT, Fought AJ, Loeb S, Meeks JJ, Kan D, and Catalona WJ. “Genetic prostate cancer risk assessment: common variants in 9 genomic regions are associated with cumulative risk.” Journal of Urology, August 2010; 184: 501.

111. Loeb S, Carvalhal GF, Kan D, Desai A, and Catalona WJ. “External Validation of the Cancer of the Prostate Risk Assessment (CAPRA) Score in a Single-Surgeon Radical Prostatectomy Series.” Urologic Oncology: Seminars and Original Investigations, September 2010 epub.

112. Carvalhal GF, Daudi SN, Kan D, Mondo D, Roehl KA, Loeb S, and Catalona WJ. “Correlation Between Serum Prostate-Specific Antigen and Cancer Volume in Prostate Glands of Different Sizes.” Urology, September 2010 epub.

113. Tosoian J and Loeb S. “PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.” TheScientificWorldJOURNAL: TSW Urology October 2010; 10: 1919–1931.

114. Mullins JK and Loeb S. “Diabetes Mellitus and Prostate Cancer Risk.” Expert Review of Endocrinology and Metabolism November 2010; 5: 787.

115.Loeb S and Partin AW. “PCA3 Urinary Biomarker for Prostate Cancer.” Reviews in Urology Fall 2010; 12: e205. PMID: 21234266.

116. Bivalacqua TJ, Loeb S, Pierorazio PM, Schoenberg MP, Partin AW, Guzzo TJ. “Is Prostate Specific Antigen Surveillance Necessary in Men with Benign Prostate Pathology Following Radical Cystoprostatectomy for Bladder Cancer?” Urologia Internationalis epub November 2010; 85: 466.

117. Loeb S, Carter HB, Schaeffer EM, Kettermann A, Ferrucci L, and Metter EJ. “Distribution of PSA Velocity by Total PSA Levels: Data from the Baltimore Longitudinal Study of Aging.” Urology January 2011; 77: 143.

118. Loeb S, Vonesh EF, Metter EJ, Carter HB, Gann PH, and Catalona WJ. “What is the true number-needed-to-screen and treat to save a life with prostate-specific antigen (PSA) testing?” Journal of Clinical Oncology January 2011; 29: 464.

119. Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, and Han M. “Significance of Preoperative PSA Velocity in Men with Low Serum PSA and Normal DRE.” World Journal of Urology February 2011; 29: 11.

120. Loeb S. “Editorial Comment Re: Evaluation of Prostate Specific Antigen Acceleration for Prostate Cancer Diagnosis.” Journal of Urology March 2011; 185: 826. PMID: 21239022.

121. Loeb S. “Germline Sequence Variants and Prostate Specific Antigen Interpretation.” Clinical Chemistry May 2011; 57: 662-3. PMID: 21411622.

122. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. “A Multicenter Study of [-2] Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range.” Journal of Urology May 2011; 185: 1650. PMID: 21419439.

123. Loeb S and Carter HB. “Should prostate-specific antigen velocity be abandoned?” Asian Journal of Andrology May 2011; 12: 359. PMID: 21499277.

124. O’Brien D, Loeb S, Carvalhal GF, McGuire BB, Kan D, Hofer MD, Casey JT, Helfand BT, and Catalona WJ. “Delay of Surgery in Men with Low Risk Prostate Cancer.” Journal of Urology June 2011; 185: 2143. PMID: 21496847.

125. Loeb S. “Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific Antigen: Pro.” Journal of Urology June 2011; 186: 17. PMID: 21571331.

126. Loeb S. “Prediction of Outcomes After Radical Prostatectomy in Patients Diagnosed with Prostate Cancer of Biopsy Gleason Score ≥8 Via Contemporary Multi (≥12)-Core Prostate Biopsy.” BJU International July 2011; 108: 222. PMID: 21718432.

127. Loeb S, Feng Z, Ross A, Trock BJ, Humphreys EB, and Walsh PC. “Can We Stop Prostate Specific Antigen Testing 10 Years After Radical Prostatectomy?” Journal of Urology August 2011; 186: 500. PMID: 21679999.

128. Loeb S. “Invited Editorial Comment Re: Variable Prostate-Specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Medical Center.” Urology August 2011; 78: 248. PMID: 21820564.

129. Loeb S. “Invited Editorial Comment Re: Long-Term Fluoroquinolone Use Before the Prostate Biopsy May Increase the Risk of Sepsis Caused by Resistant Microorganisms.” Urology August 2011; 78: 255. PMID: 21820566.

130. Cooper PR, McGuire BB, Helfand BT, Loeb S, Hu Q, and Catalona WJ. “Prostate Cancer Risk Alleles and Their Associations with Other Malignancies.” Urology October 2011; 78: 970 .e 15-20. PMID: 21820706.

131. Loeb S. Editorial comment re: “Prostate Specific Antigen Velocity per Prostate Volume: A Novel Tool for Prostate Biopsy Prediction.” Urology October 2011; 78: 879. PMID: 21982006

132. Loeb S, Metter EJ, and Carter HB. “Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection.” Journal of the National Cancer Institute November 2011; 103: 1636. PMID: 21926375.

133. Loeb S, Carter HB, Berndt SI, Ricker W, and Schaeffer EM. “Complications After Prostate Biopsy: Data From SEER-Medicare.” Journal of Urology November 2011; 186: 1830. PMID: 21926375.

134. Gupta AD, Loeb S, Stec A, and Wang MH. “Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis.” Urology December 2011; 78: 1414-6. PMID: 21676451.

135. Loeb S and Partin AW. “Imaging Utilization for the Staging of Clinically Localized Prostate Cancer.” Reviews in Urology 2011; 13: 63. PMID: 21845110.

136. Loeb S, Trock BJ. “Re: Randomized Prostate Cancer Screening Trial: 20 Year Follow-up.” European Urology 2011; 60: 1306. PMID: 22054407.

137. Brawer MK, Loeb S, Partin AW, Nirmal J, Chancellor MB, Nickel JC, Rajfer J, Shapiro E, and Roehrborn CG. “Best of the AUA Annual Meeting: Highlights from the 2011 American Urological Association Meeting, May 14-19, 2011, Washington, DC.” Reviews in Urology 2011; 13: 151-72. PMID: 22114546.

138. Banks JA, McGuire BB, Loeb S, Shrestha S, Helfand BT, Catalona WJ. “Bacteriuria and antibiotic resistance in catheter urine specimens following radical prostatectomy.” Urologic Oncology 2012, epub Jan 25. PMID: 22285005.

139. Loeb S, Carter HB, Catalona WJ, Moul JW, and Schroder FH. “Baseline Prostate-Specific Antigen Testing at a Young Age.” European Urology January 2012; 61: 1-7. PMID: 21862205.

140. Loeb S and Catalona WJ. “PSA Should Drive Doing Prostate Biopsies.” Urologic Oncology: Seminars and Original Investigations Jan-Feb 2012; 30: 1-2. PMID: 21458316.

141. Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ. “Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.” BJU International. 2012 Feb;109(4):508-13. PMID: 22296334.

142. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A. “Novel approaches to improve prostate cancer diagnosis and management in early-stage disease.” BJU International 2012; 109 Suppl 2: 1-7. PMID: 22257098.

143. Mullins JK, Loeb S. “Environmental exposures and prostate cancer.” Urologic Oncology: Seminars and Investigations, March 2012; 30: 216. PMID: 22385992.

144. Loeb S. “Editorial comment re: Longitudinal Changes of Benign Prostate-Specific Antigen and [-2]ProProstate-Specific Antigen in Seven Years in a Community-Based Sample of Men.” Urology, March 2012; 79: 661. PMID: 22386421.

145. Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, and Schroder FH. “Prediction of Prostate Cancer Risk: The Role of Prostate Volume and Digital Rectal Examination in the ERSPC Risk Calculators.” European Urology March 2012; 61: 577-83. PMID: 22104592.

146. Loeb S, Carlsson S, and Braithwaite RS. “Prostate Cancer: Modeling the Outcomes of Prostate Cancer Screening.” Nature Reviews Urology, March 2012; 13: 183-5. PMID: 224106678.

147. Loeb S, Van den Heuvel S, Zhu X, Bangma CH, Schroder FH, and Roobol MH. "Reply from the Authors re: Alexandre R. Zlotta, Robert K. Nam. To Biopsy or Not to Biopsy- Thou Shall Think Twice. Eur Urol. In press. DOI:10.1016/j.eururo.2012.01.055: Considerations for Prostate Biopsy Decisions." European Urology; 2012 March 8 epub.

148. Roobol MJ, Bangma CH, Loeb S. "Prostate-specific antigen screening can be beneficial to younger and at-risk men." CMAJ, May 2012 epub. PMID: 22566532.

149. Loeb S. “Use of Baseline Prostate-Specific Antigen Measurements to Personalize Prostate Cancer Screening.” European Urology May 2012: 61: 875-6. PMID:22154726.

150. Nichols JH, Loeb S, Metter EJ, Ferrucci L, Carter HB. “The Relationship Between Prostate Volume and Prostate-Specific Antigen Variability: Data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.” BJU International May 2012; 109: 1304-8. PMID: 22093443.

151. McGuire BB, Helfand BT, Loeb S, Hu Q, O’Brien D, Cooper P, Yang X, and Catalona WJ. “Outcomes in Patients with Gleason Score 8-10 Prostate Cancer: Relation to Preoperative PSA Level.” BJU International June 2012; 109: 1764-9. PMID: 22017732.

152. Loeb S. “Infection after Transrectal Ultrasonography-Guided Prostate Biopsy: Increased Relative Risks after Recent International Travel or Antibiotic Use.” BJU International June 2012; 109: 1785-6. PMID: 22040375.

153. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. “Infectious Complications and Hospital Admissions After Prostate Biopsy in a European Randomized Trial.” European Urology June 2012; 61: 1110-4. PMID: 22244150.

154. Loeb S, Semins MJ, and Matlaga BR. “Novel Technique for Fragment Removal After Percutaneous Management of Large-Volume Neobladder Calculi.” Urology, August 2012; 80: 474. PMID: 22857764.

155. Loeb S. “An Examination of the Dynamic Changes in Prostate-Specific Antigen Occurring in a Population-Based Cohort of Men Over Time.” BJU International August 2012; 110: 381-2. PMID: 22313542.

156. Loeb S and Borin JF. “Innovation in Endourology and Minimally Invasive Surgery. Highlights from the 29th World Congress of Endourology and SWL 2011, November 30-December 3, 2011, Kyoto, Japan.” Reviews in Urology 2012; 14: 28-30. PMID: 23172997.

157. Tosoian J and Loeb S. “Radical Retropubic Prostatectomy: Comparison of the Open and Robotic Approaches for Treatment of Prostate Cancer.” Reviews in Urology 2012; 14: 1-8. PMID: 23172996.

158. Loeb S, Zhu X, Schroder FH, Roobol MJ. “Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.” BJU International epub Sept 21, 2012. PMID: 22998182.

159. Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ. “Association of [-2]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. Journal of Urology October 2012; 188: 1131-6. PMID: 22901577.

160. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. “Is repeat prostate biopsy association with a greater risk of hospitalization? Data from SEER-Medicare.” Journal of Urology epub Oct 9, 2012. PMID: 23063634.

161. Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S. “The Impact of Anatomical Radical Retropubic Prostatectomy on Cancer Control: The 30-Year Anniversary.” Journal of Urology epub October 18, 2012. PMID: 23083655.

162. Helfand BT, Hu Q, Loeb S, McVary KT, Catalona WJ. “Genetic Sequence Variants are Associated with Severity of Lower Urinary Tract Symptoms and Prostate Cancer Susceptibility.” Journal of Urology 2012 epub November. PMID: 23159463.

163. Loeb S, Gupta A. Losonczy L, Tosoian J, Walsh PC. “Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?” Curr Opin Urol January 2013; 23: 2-4. PMID: 23159990.

164. Loeb S, Sokoll LJ, Broyles DL, Bangma CH, van Schaik RH, Klee GG, Wei JT, Sanda MG, Partin AW, Slawin KM, Marks LS, Mizrahi IA, Shin SS, Cruz AB, Chan DW, Roberts WL, Catalona WJ. “Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration.” Journal of Urology 2012; epub November. PMID: 23206426.

165. Helfand BT, Loeb S, Hu Q, Cooper PR, Roehl KA, McGuire BB, Baumann NA, Catalona WJ. “Personalized PSA Testing Using Genetic Variants May Reduce Unnecessary Biopsies.” Journal of Urology 2012; epub December. PMID: 23246478.

166. Loeb S, Drevin L, Robinson D, Holmberg E, Carlsson S, Lambe M, Stattin P. “Risk of localized and advanced prostate cancer among immigrants versus native-born Swedish men: a nation-wide population-based study.” Cancer Causes Control 2012; December epub. PMID: 23266834.

167. Loeb S. “Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker?” European Urology epub 2013 Feb 14. PMID: 23453055

168. Bangma CH, Loeb S, Susstra M, Zhu X, Bouazzaoui SE, Refos J, Van Der Keur KA, Tijn S, Franken CG, van Leenders GJ, Zwarthoff EC, Roobol MJ. “Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers.” European Urology 2013 epub March 4. PMID: 23478169

169. Loeb S, Carter HB. “Point: Impact of Prostate-Specific Antigen Velocity on Management Decisions and Recommendations.” Journal of the National Comprehensive Cancer Network March 2013; 11: 281. PMID: 23486454

170. Loeb S. “Prostate Cancer Screening and Surgical Management of Localized Disease: Highlights from the 27th Annual Congress of the European Association of Urology, February 24-28, 2012, Paris, France.” Reviews in Urology 2012; 14: 87-9. PMID: 23526727

171. Nickel JC, Partin AW, Nirmal J, Chancellor MB, Loeb S, Brawer MK, Assimos D, and Shapiro E. “Best of 2012 AUA Annual Meeting: Highlights from the 2012 American Urological Association Meeting, May 19-23, 2012, Atlanta, GA.” Reviews in Urology 2012; 14: 90-103. PMID: 23526762

172. Loeb S, Braithwaite RS, Hayes RB. “Utility of single nucleotide polymorphisms in prostate biopsy decisions.” Reviews in Urology 2012; 14: 115-7.

173. Loeb S. “Does Delaying Prostate Cancer Treatment Miss the Window of Curability?” European Urology 2013 epub Apr 8. PMID: 23619388

174. Vellekoop A and Loeb S. “Update of Randomized Trials for Prostate Cancer Screening.” Reviews in Urology 2013; 15: 37-9. PMID: 23671404

175. Loeb S, Berglund A, Stattin P. “Population-Based Study of Utilization and Determinants of Active Surveillance and Watchful Waiting for Low- and Intermediate-Risk Prostate Cancer” Journal of Urology 2013 May 29 epub. PMID: 23727309

176. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, and Lotan Y. “Systematic Review of Complications of Prostate Biopsy.” European Urology 2013; June epub.

177. Stattin P and Loeb S. “‘To measure is to know. If you cannot measure it, you cannot improve it.’ Statistical Modeling Cannot Compensate for Unmeasured Bias.” European Urology 2013; June epub.

178. Loeb S. “Editorial Comment on ‘Screening Rectal Culture to Identify Fluoroquinolone-Resistant Organisms Before Transrectal Prostate Biopsy: Do the Culture Restults Between Office Visit and Biopsy Correlate?” Urology 2013; 82: 71.

179. Makarov DV, Loeb S, Ulmert D, Drevin L, Lambe M, Stattin P. “Prostate Cancer Imaging Trends After a Nationwide Effort to Discourage Inappropriate Prostate Cancer Imaging.” Journal of the National Cancer Institute (JNCI) 2013 July epub.

180. Loeb S. “Prostate Cancer: Prostate Health Index- Improving Screening in Men with a Positive Family History.” Nature Reviews in Urology 2013; 10: 497

181. Vellekoop A and Loeb S. “Editorial Comment on A Single Dose of 240 mg Gentamicin During Transrectal Prostate Biopsy Significantly Reduces Septic Complications.” Urology 2013 epub August.

182. Vellekoop A, Loeb S, Folkvaljon Y, Stattin P. “Population-Based Study of Predictors for Adverse Pathology Among Candidates for Active Surveillance With Gleason 6 Prostate Cancer. Journal of Urology 2013 epub September 23.

183. Loeb S, Assimos D, Chancellor MB, Nickel JC, Brawer MK, Kern AJ, Partin AW. “Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA..” Reviews in Urology 2013; 15: 72.

184. Loeb S, Borin JF. “Advances in Localized Prostate Cancer: Highlights From the 2012 Friends of Israel Urological Symposium, July 3-5, 2012, Tel Aviv, Israel.” Reviews in Urology 2013; 15: 82.

185. Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wooten A, Walsh PC, Costello AJ. “The Melbourne Consensus Statement on the Early Detection of Prostate Cancer.” British Journal of Urology International 2012 epub Nov 8. PMID: 24206066

186. Loeb S. “Editorial Comment on: Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-Institution Active Surveillance Cohort.” Urology 2014; 83 (1): 38-19. PMID: 24246328

187. Loeb S, Bayne CE, Frey C, Davies BJ, Averch TD, Woo HH, Stork B, Cooperberg MR, Eggener SE. “Use of Social Media in Urology: Data from the American Urological Association.” British Journal of Urology International 2013 epub Nov 26. PMID: 24274744

188. Bjurlin MA, Walter D, Taksler GB, Huang WC, Wysock JS, Sivarajan G, Loeb S, Taneja SS, Makarov DV. “National Trends in the Utilization of Partial Nephrectomy Before and After the Establishment of AUA Guidelines for the Management of Renal Masses.” Urology 2013; 82: 1283-9. PMID: 24295245.

189. Loeb S. “The Age Old Question: Who Benefits From Prostate Cancer Treatment?” British Journal of Urology International 2013; 1134: 4. PMID: 24330057

190. Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, and Loeb S. “Prostate Cancer Risk Alleles are Associated with Prostate Cancer Tumor Volume and Prostate Size.” Journal of Urology 2013; epub Dec 14. PMID: 24345439

191. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. “Overdiagnosis and Overtreatment of Prostate Cancer.” European Urology 2014; epub Jan 9. PMID: 24439788

192. Loeb S. “Editorial Comment on: A Commentary on PSA Velocity and doubling time for clinical decisions in prostate cancer” Urology 2014; 83: 596. PMID: 24581522

193. Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, and Stattin P. “Nationwide Population-Based Study of Prostate Cancer Stage Migration Between and Within Clinical Risk Categories.” Scandinavian Journal of Urology 2014 March epub. PMID: 24581522

194. Loeb S, Catto J, Kutikov A. “Social Media Offers Unprecedented Opportunities for Vibrant Exchange of Professional Ideas Across Continents.” European Urology 2014 March epub. PMID 24630683

195. Prabhu V, Lee T, Loeb S, Holmes JH, Gold HT, Lepor H, Penson DF, and Makarov DV. “Twitter Response to the United States Preventive Services Task Force Recommendations Against Screening with Prostate Specific Antigen.” BJU International 2014 March epub. PMID: 24661474

196. Loeb S, Catalona WJ. “The Prostate Health Index: A New Test for the Detection of Prostate Cancer.” Therapeutic Advances in Urology 2014; 6: 74. PMID: 24688603

197. Donin N, Loeb S, Cooper PF, Roehl KA, Baumann NA, Catalona WJ, Helfand BT. “Genetically-Adjusted PSA Values May Prevent Delayed Biopsies in African-American Men.” BJU International 2014 Jan epub. PMID: 24712975

198. Loeb S, Cooperberg MR. “Early Detection of Prostate Cancer.” Urological Clinics of North America 2014 May epub. PMID: 24725496

199. Murphy DG, Loeb S, Basto MY, Challacombe B, Trinh QD, Leveridge M, Morgan T, Dasgupta P, Bultitude M. “Engaging Responsibly with Social Media: the BJUI Guidelines.” BJU International 2014 Apr epub. PMID: 24774415

200. Loeb S. “Editorial comment on ‘Current Ability of Multiparametric Prostate MRI and Targeted Biopsy to Improve the Detection of Prostate Cancer’” Urology Practice 2014 May; 1: 20.

201. Lundstrom KJ, Drevin L, Carlsson S, Garmo H, Loeb S, Stattin P, Bill-Axelson A. “Nationwide Population-Based Study of Infections After Transrectal Ultrasound Guided Prostate Biopsy.” Journal of Urology 2014 May epub. PMID 24813343.

202. Loeb S. Editorial Comment on "Prostate-Specific Antigen Density: Toward a Better Cutoff to Identify Better Candidates for Active Surveillance." Urology 2014; 84: 371.

203. Grin B, Loeb S, Roehl K, Cooper PR, Catalona WJ, Helfand BT. "A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease." BJU International 2014, June epub. PMID: 24952954.

204. Loeb S. "Guideline of guidelines: prostate cancer screening." BJU International 2014 September; 114: 323. PMID: 24981126.

205. Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. "Five-Year Nationwide Follow-up Study of Active Surveillance for Prostate Cancer." Eur Urol 2014, June epub.

206. Loeb S. "Prostate Cancer Screening Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014." Reviews in Urology 2014; 16: 90. PMID: 25009450.

207. Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. "Upper Limit of Cancer Extent on Biopsy Defining Very Low Risk Prostate Cancer." BJU International 2014, July epub. PMID: 25053197.

208. Loeb S. Editorial Comment on: “Outcomes of Fecal Carriage of Extended-Spectrum β-Lactamase After Transrectal Ultrasound-Guided Biopsy of the Prostate.” Urology 2014, September epub. PMID 25239260.

209. Bayne CE, Murphy DG, Loeb S. "#Urology is Trending in Social Media." Reviews in Urology 2014; 16: 152. PMID: 25337049.

210. Lundon D, Loeb S. "Prostate-Specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer." Reviews in Urology 2014; 16: 154. PMID: 25337050.

211. Davuluri M, Loeb S. "Prevalence of Infections Associated with Prostate Biopsy." Reviews in Urology 2014; 16: 156. PMID: 25337051.

212. Loeb S, Peskoe SB, Joshu CE, Huang WY, Hayes RB, Carter HB, Isaacs WB, Platz EA "Do Environmental Factors Modify the Genetic Risk of Prostate Cancer?" Cancer Epidemiology Biomarkers Prevention 2015; 24: 213. PMID: 25342390.

213.Loeb S. Editorial Comment on "Incidence and management of extended-spectrum beta-lactamase and quinolone-resistant Escherichia coli infections after prostate biopsy." Urology 2014; 84: 1006-7. PMID: 25443895.

214. Loeb S. Editorial Comment on "Low percentage of free prostate-specific antigen (PSA) is a strong predictor of later detection of prostate cancer among Japanese men with serum levels of total PSA of 4.0 ng/mL or less" Urology 2014; 84: 1167. PMID: 25443924.

215. Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ. "Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification." European Urology 2014 Oct epub. PMID: 25457014

216. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. "The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer." Journal of Urology 2014 Nov 15 epub. PMID:25463993

217. Loeb S. "Is Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy Ready for 'Prime Time'?" European Urology 2014 Nov epub. PMID: 25465339.

218. Loeb S. Editorial comment on "Prevalence and predictive factors of harboring fluoroquinolone-resistant and extended-spectrum β-lactamase-producing rectal flora in Hong Kong Chinese men undergoing transrectal ultrasound-guided prostate biopsy." Urology 2015; 85: 21-2. PMID 25530360

219. Loeb S. Editorial Comment on "Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk." Urology 2015; 85: 170. PMID: 25530380.

220. Loeb S, Carter HB, Schwartz M, Fagerlin A, Braithwaite RS, Lepor H. "Heterogeneity in active surveillance protocols worldwide." Reviews in Urology 2014;16(4):202-3. PMID: 25548550.

221.Loeb S. "Social media makes global urology meetings truly global." BJU International 2015 Feb; 115(2):175. PMID: 25604713

222. Loeb S. "Prostate cancer: Predicting prostate biopsy results- PCA3 versus phi." Nature Reviews Urology 2015 epub Feb 3. PMID: 25644161

223. Loeb S, Montorsi F, Catto JW. “Future-Proofing Gleason Grading: What to Call Gleason 6 Prostate Cancer?” European Urology 2015 epub. PMID: 25769986.

224. Loeb S. “Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that PHI consistently outperforms PSA across diverse populations.” BJU International 2015; 115: 500. PMID: 25808708

225. Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L, Franck Lissbrant I, Makarov D, Loeb S, Stattin P. “Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.” European Urology 2015 epub. PMID: 25813688.

226. Loeb S. Editorial Comment on: “For Single Dosing, Levofloxacin is Superior to Ciprofloxacin When Combined With an Aminoglycoside in Preventing Severe Infections After Prostate Biopsy.” Urology 2015 epub. PMID: 25863839.

227. Bostrӧm PJ, Bjartell AS, Catto JW, Eggener SE, Lilja H, Loeb S, Schalken J, Schlomm T, and Cooperberg MR. “Genomic Predictors of Outcome in Prostate Cancer.” European Urology 2015 epub. PMID: 25913390.

228. Carlsson S, Drevin L, Loeb S, Widmark A, Frank Lissbrant I, Robinson D, Johansson E, Stattin P, and Fransson P. “Population-based study of long-term functional outcomes after prostate cancer treatment.” BJU International 2014 epub. PMID: 25959859.

229. Loeb S. “Prostate Biopsy Decisions: One Size Fits All Approach with Total PSA is Out and a Multivariable Approach with the Prostate Health Index is In.” BJU International 2015 June epub. PMID: 26054000

230. Loeb S. Editorial Comment on “Digital Identity: Develop One Before You’re Given One.” Urology 2015; 85: 1222. PMID: 26099864

231. Loeb S, Folkvaljon Y, Lambe M, Robinson D, Garmo H, Ingvar C, Stattin P. “Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.” JAMA 2015; 313: 2449-55. PMID: 26103029.

232. Borgmann H, Wölm JH, Vallo S, Mager R, Huber J, Breyer J, Salem J, Loeb S, Haferkamp A, Tsaur I. "Prostate Cancer on the Web- Expedient Tool for Patients' Decision-Making?" Journal of Cancer Education 2015 epub Aug 4. PMID: 26234650.

233. Loeb S, Schlomm T, Stattin P. "Associations Do Not Equal Causation: Clinical Relevance of Statistical Associations of Phosphodiesterase Type 5 Inhibitors with Prostate Cancer Progression and Melanoma." European Urology 2015 epub July. PMID: 26238432.

234. Loeb S. Editorial Comment on "Trends in Prostate Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012." Urology 2015; 86: 504-5.

235. Murphy DG, Loeb S. "Prostate Cancer: Growth of AS in the USA Signals Reduction in Overtreatment." Nature Reviews Urology 2015 epub. PMID: 26390970.

236. Loeb S, Ribal MJ. "Controversies in Management of High-Risk Prostate and Bladder Cancer." BJU International 2015 Nov; 116: 675. PMID: 26449166.

237. Loeb S. "Re: Long-Term Follow-up of a Large Active Surveillance Cohort of Patients with Prostate Cancer." European Urology 2015 Nov; 68: 907. PMID: 26460874.

238. Nickel JC, Gorin MA, Partin AW, Assimos D, Brawer M, Nicolai H, Chancellor MB, Goggins Á, Loeb S, Shapiro E. "Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA." Reviews in Urology. 2015;17(3):179-89. PMID: 26543434

239. Lepor A, Catalona WJ, Loeb S. "The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics North America. 2016 Feb;43(1):1-6. PMID: 26614024

240. Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for Familial and Hereditary Prostate Cancer. International Journal of Cancer. 2015 Dec 5 epub. PMID: 26638190

241. Thomsen FB, Folkvaljon Y, Garmo H, Robinson D, Loeb S, Ingvar C, Lambe M, Stattin P. "Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study." International Journal of Cancer. 2015 Dec 14 epub. PMID: 26662367

242. Borgmann H, DeWitt S, Tsaur I, Haferkamp A, Loeb S. "Novel survey disseminated through Twitter supports its utility for networking, disseminating research, advocacy, clinical practice and other professional goals." Canadian Urological Association Journal. 2015 Sep-Oct;9(9-10):E713-7. Epub 2015 Oct 13. PMID: 26664662

243. Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. "Evaluation of the 2015 Gleason Grade Groups in a Nationwide Population-based Cohort." European Urology. 2015 Dec 17 epub. PMID: 26707871

244. Sun M, Choueiri TK, Hamnvik OR, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD. "Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy." JAMA Oncology. 2015 Dec 23:1-8 epub. PMID: 26720632

245. Loeb S, Folkvaljon Y, Robinson D, Schlomm T, Garmo H, Stattin P. "Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment." European Urology. 2015 Dec 29 epub. PMID: 26743040

246. Björklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, Stattin P, Akre O. "Ninety-Day Postoperative Mortality after Robot-assisted Laparoscopic Prostatectomy and Retropubic Radical Prostatectomy. Nation-wide population-based study." BJU International 2016 Jan 13 epub. PMID: 26762928

247. Loeb S, Lambe M, Stattin P. “Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D.F. Penson J Urol 2015; 194: 1710-1711.” Journal of Urology 2016 epub. PMID: 26783933

248.Danneman D, Drevin L, Delahunt B, Samaratunga H, Robinson D, Bratt O, Loeb S, Stattin P, Egevad L. "The Accuracy of Prostate Biopsies for Predicting Gleason Score in Radical Prostatectomy Specimens. Nationwide trends 2000-2012." BJU International. 2016 Feb 25 epub. PMID:26918298.

249. Lundström KJ, Folkvaljon Y, Loeb S, Axelson AB, Stattin P, Nordin P. "Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy." Scandinavian Journal of Urology. 2016 Mar 3:1-5 epub. PMID: 26936203.

250. Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV. "How Active is Active Surveillance? Intensity of Follow-Up During Active Surveillance for Prostate Cancer in the United States." Journal of Urology 2016 Mar 2 epub. PMID: 26946161.

251.Tosoian JJ, Carter HB, Lepor A, Loeb S. "Active surveillance for prostate cancer: current evidence and contemporary state of practice." Nature Reviews Urology 2016 Mar 8 epub. PMID: 26954332.

252. Borgmann H, Woelm JH, Merseburger A, Nestler T, Salem J, Brandt MP, Haferkamp A, Loeb S. "Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference." Canadian Urological Association Journal 2016 Jan-Feb;10(1-2):39-44. PMID: 26977205.

253. Borghmann H, Loeb S, Salem J, Thomas C, Haferkamp A, Murphy DG, Tsaur I. “Activity, content, contributors, and influencers of the twitter discussion on urologic oncology.” Urologic Oncology 2016 epub. PMID: 27036217.

254. Loeb S, Folkvaljon Y, Robinson D, Makarov DV, Bratt O, Garmo H, and Stattin P. “Immediate versus delayed prostatectomy: Nationwide population-based study.” Scandinavian Journal of Urology 2016 Apr 12 epub. PMID: 27067998.

255. Loeb S. “Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harms?” European Urology 2016 April epub. PMID: 27090973.

256. Loeb S, Stattin P. "Further Evidence against a Causal Association between Erectile Dysfunction Drugs and Melanoma." European Urology 2016 Jul 16 epub. PMID: 27436160.

257. Mata DA, Tilak G, Loeb S, Ramasamy R. "Curating a Digital Identity: What Urologists Need to Know About Social Media." Urology 2016 Jul 6 epub. PMID: 27395795.

258. Loeb S. "Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening." Journal of Clinical Oncology 2016 Jun 20 epub. PMID: 27325846.

259. Loeb S, Curnyn C, Sedlander E. “Perspectives of Prostate Cancer Patients on Gleason Scores and the New Grade Groups: Initial Qualitative Study.” European Urology 2016 Jun 6 epub. PMID: 27283215.

260. Loeb S, Lilja H, Vickers A. “Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.” Current Opinion in Urology 2016 Jun 3 epub. PMID: 27262138

261. Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM. “Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.” American Society of Clinical Oncology Educational Book. 2016;35:e235-45. PMID: 27249729

262. Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA. "An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care." Urology. 2016 Jul 19 epub. PMID: 27450937.

263. Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, Weidner W, Loeb S. "Complications After Systematic, Random, and Image-guided Prostate Biopsy." European Urology. 2016 Aug 16 epub. PMID: 27543165.

264. Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E. "A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance." BJU International. 2016 epub. PMID: 27611479.

265. Loeb S, Meyer C, Krasnova A, Curnyn C, Reznor G, Lepor H, Kibel AS, Trinh QD. "Risk of Small Bowel Obstruction After Robot-Assisted Versus Open Radical Prostatectomy." Journal of Endourology. 2016 Sep 11 epub. PMID: 27615204

267. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RH, Slawin KM, Marks LS, Catalona WJ. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU International. 2016 Oct 15. PMID: 27743489

268. Loeb S, Folkvaljon Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden. JAMA Oncology. 2016 Oct 20. PMID: 27768168.

269. Thomsen FB, Folkvaljon Y, Brasso K, Loeb S, Robinson D, Egevad L, Stattin P. Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. J Surg Oncol. 2016 Nov;114(6):664-670. PMID: 27511833.

270. Nickel JC, Gorin MA, Alan W P, Loeb S, Ellen S, Chancellor MB, Assimos DG, Brawer MK, Brucker BM. Best of the 2016 AUA Annual Meeting: Highlights From the 2016 American Urological Association Annual Meeting, May 6-10, 2016, San Diego, CA. Reviews in Urology. 2016;18(3):159-173. PMID: 27833468.

271. Adam M, Tennstedt P, Lanwehr D, Tilki D, Steuber T, Beyer B, Thederan I, Heinzer H, Haese A, Salomon G, Budäus L, Michl U, Pehrke D, Stattin P, Bernard J, Klaus B, Pompe RS, Petersen C, Huland H, Graefen M, Schwarz R, Huber W, Loeb S, Schlomm T. Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology. 2016 Nov 22. PMID: 27887941

272. Loeb S. Editorial Comment on "Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices." Journal of Urology 2016 epub Nov 28. PMID: 27908693.

273. Choyke PL and Loeb S. "Active Surveillance of Prostate Cancer." Oncology (Williston Park) 2017; 31 (1). PMID 8090626

274. Loeb S. "When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance." Journal of Urology 2017 epub. PMID 28110035

275. Loeb S, Roupret M, Van Oort I, N'dow J, Van Gurp M, Bloemberg J, Darraugh JA, Ribal M. Novel Use of Twitter to Disseminate and Evaluate Adherence with Clinical Guidelines by the European Association of Urology. BJU International 2017 Feb 7 epub. PMID: 28170154

276. Dani H, Loeb S. "The Role of Prostate Cancer Biomarkers in Undiagnosed Men." Current Opinion Urology 2017; 27: 210-216. PMID 28212119

277. Liss MA, Ehdaie B, Loeb S, Meng MV, Raman JD, Spears V, Stroup SP. An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy. Journal of Urology 2017 Mar 29 epub. PMID: 28363690

278. O'Connor EM, Nason GJ, O'Kelly F, Manecksha RP, Loeb S. "Newsworthiness vs scientific impact: are the most highly cited urology papers the most widely disseminated in the media?" BJU International 2017 Apr 18 epub. PMID: 28418091

279. Loeb S, Folkvaljon Y, Damber JE, Alukal J, Lambe M, Stattin P. Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. Journal of Clinical Oncology 2017;35(13):1430-1436. PMID: 28447913.

280. Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight C, Borgmann H. Tweet this: how advocacy for breast and prostate cancers stacks up on social media. BJU International 2017 May epub. PMID: 28471484

281. Sternberg KM, Loeb SL, Canes D, Donnelly L, Tsai MH. The use of Twitter to facilitate sharing of clinical expertise in urology. J Am Med Inform Assoc. 2017 epub Jun 7. PMID: 28591771.

282. Loeb S. Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era. BJU International. 2017 Jul;120(1):3-4. PMID: 28621058

283. Loeb S, Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Current Opinion in Urology. 2017 Jun 28 epub. PMID: 28661898

284. Ciprut S, Curnyn C, Davuluri M, Sternberg K, Loeb S. Twitter Activity Associated with US News and World Report Reputation Scores for Urology Departments. Urology. 2017 Jun 29 epub. PMID: 28669746.

285. Loeb S. Re: The Prostate Health Index Adds Predictive Value to Multi-parametric MRI in Detecting Significant Prostate Cancers in a Repeat Biopsy Population. European Urology. 2017 Jul 4 epub. PMID: 28687144

286. Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. European Urology 2017 Aug 22 epub. PMID: 28844371

287. Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Ciprut S, Sedlander E. Informational needs during active surveillance for prostate cancer: A qualitative study. Patient Education Counseling 2017 Sep 1 epub. PMID: 28886974

288. Loeb S. Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients. Urology Practice. 2017 Jul;4(4):315-321. PMID: 29104903

289. Loeb S. Educational intervention in prostate cancer. BJU International 2017 Nov; 120(5B):E3. PMID: 29105995

290. Loeb S, Dani H. Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators. Urol Clin North Am. 2017 Nov; 44(4):517-524. PMID: 29107268

291. Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P. Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma. J Natl Cancer Inst. 2017 Aug 1;109(8). PMID: 29117385

292. Loeb S. Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer. European Urology. 2017 Nov 20. PMID: 29169932

293. Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology. 2017 Nov 29 epub. PMID: 29185869

294. Punnen S, Freedland SJ, Polascik TJ, Loeb S, Risk MC, Savage S, Mathur SC, Uchio E, Dong Y, Silberstein JL. A Multi-institutional Prospective Trial in the Veterans Affairs Health System confirms the 4Kscore maintains its Predictive value among African American Men. Journal of Urology 2017, epub Dec 6. PMID: 29223389

295. Stattin P, Sandin F, Loeb S, Robinson D, Lissbrant IF, Lambe M. Public online reporting from a nationwide population-based clinical prostate cancer register. BJU International 2018 Jul; 122(1):8-10. PMID: 29577561.

296. Loeb S, Tosoian JJ. Biomarkers in Active Surveillance. Translational Andrology and Urology 2018 Feb; 7(1):155-159. PMID: 29594029.

297. Loeb S, Katz MS, Langford A, Byrne N, Ciprut S. Prostate Cancer and Social Media. Nature Reviews Urology 2018 Apr 11. PMID: 29643501.

298. Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E. Health state utilities among contemporary prostate cancer patients on active surveillance. Translational Andrology and Urology. 2018 Apr; 7(2):197-202. PMID: 29732277.

299. Loeb S, Taneja S, Walter D, Zweifach S, Byrne N. Crowd-Funding for Prostate Cancer and Breast Cancer. BJU International. 2018 May 22. PMID: 29786946

300. Loeb S, Byrne N, Makarov DV, Lepor H, Walter D. Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015. JAMA. 2018 Jun 5; 319(21):2231-2233. PMID: 29800017

301. Borgmann H, Cooperberg M, Murphy D, Loeb S, N'Dow J, Ribal MJ, Woo H, Rouprêt M, Winterbottom A, Wijburg C, Wirth M, Catto J, Kutikov A. "Online Professionalism-2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media." European Urology 2018 Aug epub. PMID:30177286

302. Loeb S, Folkvaljon Y, Bratt O, Robinson D, Stattin P. Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance. Journal of Urology. 2018 Sep 18 epub. PMID: 30240688.

303. Loeb S. Active Surveillance for Prostate Cancer. Reviews in Urology 2018; 20: 101-103. PMID: 30288148.

304. Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A. Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube. European Urology. 2018 Nov 27 epub. PMID: 30502104. (Featured as a Highlight on the Cover of the April 2019 issue)

305. Drangsholt S, Walter D, Ciprut S, Lepor A, Sedlander E, Curnyn C, Loeb S, Malloy P, Winn AN, Makarov DV. Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. Urologic Oncology 2019 Feb;37(2):145-149. PMID: 30578160.

306. Loeb S, Taylor J, Butaney M, Byrne NK, Gao L, Soule HR, Miyahira AK. Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination. European Urology 2019 Jan 30 epub. PMID: 30711329. (Featured as a Highlight on the Cover of the May 2019 issue)

307. Ke Y, Taylor J, Gao L, Wang H, Zhao H, Byrne N, Modgil V, Butaney M, Makarov DV, Prabhu V, Loeb S. Twitter response to the 2018 US Preventive Services Task Force guidelines on prostate cancer screening. BJU International 2019 Feb 27 epub. PMID: 30811805

308. Fine ND, LaPolla F, Epstein M, Loeb S, Dani H. Genomic Classifiers for Treatment Selection in Newly Diagnosed Prostate Cancer. BJU International 2019 May epub. PMID:31055874.

309. Loeb S. Overactive Surveillance: Is "Conservative" Management for Low-risk Prostate Cancer Too Aggressive? Eur Urol. 2019 May epub. PMID:31060823

310. Becker DJ, Iyengar AD, Punekar SR, Ng J, Zaman A, Loeb S, Becker KD, Makarov D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Res. 2019 May;39(5):2467-2473. PMID: 31092441

311. Langford A, Loeb S. Perceived Patient-Provider Communication Quality and Sociodemographic Factors Associated With Watching Health-Related Videos on YouTube: A Cross-Sectional Analysis. J Med Internet Res. 2019 May 17;21(5):e13512. PMID:31102372

312. Loeb S, Katz MS, Stork B. Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology. Eur Urol. 2019 Jun epub. PMID: 31164252

312. Stork B, Loeb S. The Urology Care Foundation - trusted online resources in an era of misinformation. Nature Reviews Urology 2019 Jul 12 epub. PMID: 31300752

313. Loeb S, Carrick T, Frey C, Titus T. Increasing Social Media Use in Urology: 2017 American Urological Association Survey. European Urology Focus. 2019 Jul 24 epub. PMID: 31351900

314. Teoh JY, Mackenzie G, Smith M, Yuen SK, Gudaru K, Leow J, Leung CH, Ng CF, Loeb S. Understanding the Composition of a Successful Tweet in Urology. Eur Urol Focus. 2019 Aug 27 epub. PMID:31471219

315. Langford AT, Roberts T, Gupta J, Orellana KT, Loeb S. Impact of the Internet on Patient-Physician Communication. Eur Urol Focus. 2019 Sep 30 epub. PMID: 31582312

316. Loeb S, Cazzaniga W, Robinson D, Garmo H, Stattin P. Opioid Use After Radical Prostatectomy: Nationwide, Population-Based Study in Sweden. J Urol. 2019 Jul 17 epub. PMID:31584849

317. Butler SS, Loeb S, Cole AP, Zaslowe-Dude C, Muralidhar V, Kim DW, Schaeffer EM, Trinh QD, Nguyen PL, Mahal BA. United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer Prostatic Dis. 2019 Oct 7 epub. PMID: 31591454.

318.Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Leong JY, Liem S, Teplitsky S, Noorani R, Loeb S. Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019. British Journal of Urology International. 2019 Oct 10 epub. PMID: 31602782.

319. Taylor J, Loeb S. Guideline of guidelines: social media in urology. British Journal of Urology International. 2019 Oct 20 epub. PMID: 31631471.

320.Thangasamy IA, Loeb S, Sathianathen NJ, Leveridge M, Stork B, Davies BJ, Woo HH. Evaluating the Effectiveness of an Online Journal Club: Experience from the International Urology Journal Club. European Urology Focus. 2019 Oct 31 epub.PMID:31679867

321. Loeb S, Salter CA, Nelson CJ, Mulhall JP, Wittmann D. A Call to Arms: Increasing Our Understanding of the Impact of Prostate Cancer on the Sexual Health of Partners. Journal of Sexual Medicine. 2019 Dec 10 epub. PMID: 31836299.

322. Loeb S, Taylor J, Borin JF, Mihalcea R, Perez-Rosas V, Byrne N, Chiang AL, Langford A. Fake News: Spread of Misinformation about Urological Conditions on Social Media. European Urology Focus. 2019 Dec 21 epub.  PMID: 31874796.

Book Chapters1. Catalona WJ, Loeb S, and Han M. “Prostate-Specific Antigen.” For Prostate Biopsy:

Indications, Techniques, and Complications, edited by Eric Klein, Cleveland Clinic. Humana Press 2008.

2. Loeb S. “Paracentesis.” For Surgical Pitfalls, edited by Steven R.T. Evans, Georgetown University. Elsevier, Inc. 2009.

3. Makarov DV, Loeb S, Getzenberg RH, and Partin AW. “Biomarkers for Prostate Cancer.” For Annual Reviews in Medicine, February 2009.

4. Loeb S and Carter HB. “Early Detection, Diagnosis, and Staging of Prostate Cancer.” For Campbells-Walsh (10th Edition). Elsevier Saunders, 2012.

5. Loeb S and Isaacs WB. “Genetic Basis for Prostate Cancer.” For Recent Advances in Prostate Cancer. World Scientific Publishing Co., July 2011.

6. Loeb S and Catalona WJ. “Early Detection of Prostate Cancer with PSA.” For Comprehensive Textbook of Genitourinary Oncology (4th Edition). Lippincott Williams & Wilkins, 2011.

7. Loeb S and Isaacs WB. “Genetic Basis of Prostate Cancer.” For Comprehensive Textbook of Genitourinary Oncology (4th Edition). Lippincott Williams & Wilkins, 2011.

8. Loeb S. “Localized Prostate Cancer.” Handbook of Urology, edited by Wiley-Blackwell, 2014.9. Loeb S and Eastham J. "Diagnosis and Staging of Prostate Cancer." For Campbells-Walsh (11th

Edition). Elsevier, 2016.10. Dani H and Loeb S. “Optimal Use of PSA.” For Practical Tips in Urology. Springer Verlag

London, 2017.11. Dr. Patrick Walsh's Guide to Surviving Prostate Cancer. Contributor Chapters 5 and 6. Grand

Central Life & Style, Hachett Book Group, 2018.12. Tosoian JJ, Alam R, Lepor A, Loeb S. The Update of Active Surveillance Around the World:

Utilization and Outcomes. For Active Surveillance for Localized Prostate Cancer (2nd Edition, Editor Klotz). Springer International Publishing, 2018.